Compounds, compositions and methods for treating or delaying non-communicable diseases

Ksp37, administered with polar compounds, targets immune pathways to reduce inflammation and oxidative stress, addressing the limitations of current treatments for non-communicable diseases by restoring immune balance and supporting cellular repair.

WO2026126051A2PCT designated stage Publication Date: 2026-06-18VIRO GEN (PTY) LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
VIRO GEN (PTY) LTD
Filing Date
2025-12-08
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments for non-communicable diseases such as biological aging, autoimmune diseases, and neurodegenerative diseases primarily focus on symptom management with significant side effects and limited ability to address underlying mechanisms, necessitating safer and more targeted therapeutic approaches.

⚗Method used

Administration of Killer-specific Secretory Protein 37 (Ksp37) with polar compounds like DMF or DMSO to modulate immune pathways, increasing therapeutic concentrations to 400 ng/mL, which activates cytotoxic immune cells and balances cytokine profiles, reducing chronic inflammation and oxidative stress.

🎯Benefits of technology

Ksp37 modulates immune responses to restore homeostasis, reduce inflammation, and support cellular repair, thereby delaying disease progression and improving cellular function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000015_0002
    Figure IMGF000015_0002
  • Figure IMGF000018_0001
    Figure IMGF000018_0001
Patent Text Reader

Abstract

This invention relates to compounds, compositions and methods for treating or delaying non-communicable diseases, including biological ageing, autoimmune disorders, and neurodegenerative or neurological conditions, by modulating immune and inflammatory pathways through Killer-specific Secretory Protein 37 (Ksp37). The invention provides for the administration of Ksp37, or stimulation of endogenous Ksp37 production using polar compounds such as DMF or dimethylsulfoxide DMSO, to increase Ksp37 levels in a subject to therapeutically effective concentrations. Elevated Ksp37 supports cytotoxic CD8+ T-cell and NK-cell activation, promotes regulatory cytokine balance, reduces chronic inflammation and oxidative stress, and enhances cellular repair mechanisms linked to ageing and immune dysregulation. These approaches restore immune homeostasis, mitigate ageing-related cellular decline, and improve outcomes in subjects affected by ageing, autoimmune disease or neurodegenerative conditions.
Need to check novelty before this filing date? Find Prior Art